Clinical Trial Update: A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

This Phase 4 study evaluates switching stable kidney transplant recipients from cyclosporine to Advagraf (tacrolimus extended-release) and compares outcomes wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Advagraf (tacrolimus)
• CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: Astellas Pharma Korea, Inc. | Conditions: Kidney Transplant | Phase 4 | Status: COMPLETED